BioSpace News Archive

Beckman Coulter Diagnostics today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

Beckman Coulter Diagnostics and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

Neuronetics, Inc. (NASDAQ: STIM) announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has authorized multiple features of NeuroStar TMS (transcranial magnetic stimulation) for sale and distribution in the country – including an expansion of the indication to now include patients with major depressive disorder (MDD) that exhibit comorbid anxiety symptoms, the NeuroStar 3.7 platform, MT Cap, and D-Tect™ MT Accessory.

Novan, Inc. and its wholly owned subsidiary, EPI Health, LLC, announced that it has entered into a stalking horse asset purchase agreement with Ligand Pharmaceuticals, Inc. prior to filing voluntary petitions for relief under chapter 11 of title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.

Elevar Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for its investigational drug rivoceranib.

Adcentrx Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application of ADRX-0706 for the treatment of select advanced solid tumors.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (Nasdaq: NOVN) (“Novan”) for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded.

BrainStorm Cell Therapeutics Inc. today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,054,055 shares of the Company’s common stock and warrants to purchase up to an aggregate of 4,054,055 shares of common stock in a registered direct offering.

Sapphiros, a platform dedicated to building the next generation of consumer diagnostics, is pleased to announce the appointment of Andrew Garfield as its new Vice President of Operations.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced its 2nd positive IMX-110 interim update from the Company’s ongoing Phase 1b/2a IMMINENT-01 (NCT05840835) study of IMX-110 in combination with BeiGene’s anti-PD-1 antibody tislelizumab.